In this review, Marinos Dalakas describes the clinical features of sporadic inclusion body myositis, and considers potential disease mechanisms and therapeutic strategies.

Proceeds to support completion of the registrational Phase 2/3 MUSCLE trial of ulviprubart in inclusion body myositis, BLA filing, and commercial launch preparation NEWTON, Mass., February 12 ...

Peter Frampton is struggling with the muscle disease inclusion body myositis and says it's affecting his ability to play music — but he'll never stop trying.

Inclusion body myositis is the most common type of late-onset inflammatory myopathy Inclusion body myositis is an idiopathic inflammatory myopathy. Whether its cause is primarily autoimmune or ...

The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant ...

Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains unknown, lacking validated models, biomarkers and effective treatment ...

Myositis is a debilitating disease that causes continuing inflammation and deterioration of muscles throughout the body and as of now, there is no known cure.

Myositis, a chronic inflammatory disease affecting the muscles, can be classified into various subtypes, including dermatomyositis, polymyositis, and inclusion body myositis.

SAN DIEGO — Many patients who might have previously been diagnosed with polymyositis are now being treated for inclusion body myositis, according to a speaker at the Congress of Clinical ...

Proceeds to support completion of Phase 2/3 registrational trial of ABC008, a first-in-class anti-KLRG1 antibody for the treatment of inclusion body myositis as well as continued development of ...

Frampton first revealed his Inclusion Body Myositis diagnosis in 2019 to CBS This Morning: Saturday.